CompoAtlas

Peau radieuse au réveil

Food supplement declared in France, declaration No 2022-12-1388

Peau radieuse au réveil (VITAVEA - Laboratoires Vitarmonyl) is a food supplement declared in France. Status: withdrawal from the market announced for 29 December 2028. Main ingredients: Viola tricolor 150 mg per day, Tanacetum parthenium 50 mg per day, Crataegus laevigata 24 mg per day, Rosa centifolia 5 mg per day, Vitamin E. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.

Brand
VITAVEA - Laboratoires Vitarmonyl
Food business operator placing the product on the market
Laboratoires VITARMONYL
Status
Withdrawal from the market announced for 29 December 2028
Form
Capsule
Daily dose
1 gélule
Directions for use
Avaler avec un verre d'eau, le soir avant le coucher
Objectives stated by the manufacturer (these are not authorised claims)
Skin

Declaration 190716, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Viola tricolor L.Parties aériennesExtrait sec aqueux150 mg
Tanacetum parthenium (L.) Sch.Bip.Parties aériennesPoudre (de plantes séchées ou broyées)50 mg
Crataegus laevigata (Poir.) DC.Sommités fleuriesExtrait sec aqueux24 mg
Rosa centifolia L.FleurExtrait sec hydroalcoolique5 mg

Other active ingredients

NamePer day
Hyaluronate de sodiumnot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
DL-alpha-tocopheryl acetateVitamin E300 mg30 mg

Additives

E470b, E504

Other ingredients

Gélule végétale

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Label warnings

Ne pas dépasser la dose recommandée. A consommer dans le cadre d'une alimentation variée et équilibrée et un mode de vie sain. A conserver dans un endroit sec et frais. Garder hors de portée des enfants.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Tanacetum parthenium (L.) Sch.Bip.
    Read the warning, when it applies and the studies cited

    FEVERFEW - TANACETUM PARTHENIUM

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Biggs et al. 1982).

    Sources cited by Health Canada (2)
    • Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. Lancet 1982;320(8301):776. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are breastfeeding (Boon 2000).

    Sources cited by Health Canada (1)
    • Boon H. Feverfew. In: Chandler F, editor. Herbs: Everyday Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association and the Canadian Medical Association; 2000.

    Contraindications

    Applies to products providing 250 mg or less of dried herb top and/or leaf, per day.

    Do not use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.

    Applies to products providing more than 250 mg of dried herb top and/or leaf, per day.

    Do not use if you are pregnant or breastfeeding (EMA 2020).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: All products.

    Stop use if hypersensitivity/allergy occurs (EMA 2020; Paulsen et al. 2001; Hausen 1996).

    Sources cited by Health Canada (2)
    • Hausen BM. A 6-year experience with compositae mix. American Journal of Contact Dermatitis 1996;7(2):94-99. PubMed
    • Paulsen E, Anderson KE and Hausen BM. Sensitization and cross-reaction patterns in Danish Compositae-allergic patients. Contact Dermatitis 2001;45(4):197-204. PubMed

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product you may experience sore mouth, mouth ulcers and/or gastrointestinal discomfort/disturbances (EMA 2020; Gardner and McGuffin 2013; Murphy et al. 1988; Johnson et al. 1985).

    Sources cited by Health Canada (3)
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Ration (FL): Taylor and Francis Group; 2013.
    • Johnson ES, Kadam NP, Hylands DM, Hylands PJ. 1985. Efficacy of feverfew as prophylactic treatment of migraine. British Medical Journal 291(6495):569-573.
    • Murphy JJ, Heptinstall S, Mitchell JR. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;332(8604):189-192.

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

  • Crataegus laevigata (Poir.) DC.
    Read the warning, when it applies and the studies cited

    Hawthorn

    Route of administration: Oral (ESCOP 2009; Bradley 2006; Mills and Bone 2000)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking cardiac glycosides (e.g., digoxin) or blood pressure or heart medications (Brinker 2010; Bradley 2006).

    Sources cited by Health Canada (2)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have chest pain, irregular heartbeat, or shortness of breath.

    Health Canada monograph dated 31 July 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : VITAVEA - Laboratoires Vitarmonyl

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Peau radieuse au réveil (VITAVEA - Laboratoires Vitarmonyl): composition and regulation”, https://compoatlas.com/en/supplements/products/190716-peau-radieuse-au-reveil, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line